ARTICLE | Clinical News
EMA's CHMP recommends Orencia in psoriatic arthritis
July 6, 2017 6:29 PM UTC
EMA’s CHMP recommended a label expansion for Orencia abatacept (ONO-4164IV) from Bristol-Myers Squibb Co. (NYSE:BMY) to include treatment of active psoriatic arthritis in adults for whom previous disease-modifying anti-rheumatic drug (DMARD) therapy, including methotrexate, has been inadequate and for whom additional systemic therapy is not required. The recommended indication includes monotherapy and combination therapy with methotrexate...
BCIQ Company Profiles